Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

被引：0

作者：

Asai, Katsunori

Narita, Yoshitaka

Nagane, Motoo

Mishima, Kazuhiko

Terui, Yasuhito

Arakawa, Yoshiki

Yonezawa, Hajime

Fukuhara, Noriko

Sugiyama, Kazuhiko

Shinojima, Naoki

Aoi, Arata

Nishikawa, Ryo

机构：

[1] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan

[2] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan

[3] Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo, Japan

[4] Saitama Med Univ Int Med Ctr, Dept Neurooncol Neurosurg, Saitama, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan

[6] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan

[7] Kagoshima Univ Hosp, Dept Neurosurg, Kagoshima, Japan

[8] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan

[9] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan

[10] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima, Japan

[11] Kumamoto Univ Hosp, Dept Neurosurg, Kumamoto, Japan

[12] Ono Pharmaceut Co LTD, Dept Clin Dev, Osaka, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7548

引用

页数：1

共 50 条

[31] Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Bouabdallah, Krimo
Khanal, Rashmi
Topp, Max S.
Houot, Roch
Beitinjaneh, Amer
Peng, Weimin
Fang, Xiang
Shen, Rhine R.
Siddiqi, Rubina
Kloos, Ioana
Reagan, Patrick M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 555 - +
[32] Salvage Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Hyung, Jaewon
Hong, Jung Yong
Yoon, Dok Hyun
Lee, Kyoungmin
Kim, Shin
Park, Chan-Sik
Huh, Jooryung
Ryu, Jin-Sook
Suh, Cheolwon
BLOOD, 2017, 130
[33] Defining MRI-based follow-up protocol for primary central nervous system lymphoma
Puhakka, Inka K.
Sunela, Kaisa L.
Ronka, Aino L.
Rajamaki, Aino M.
Arkko, Ulla-Mari
Klaavuniemi, Tuula M.
Kuusisto, Milla E. L.
Jakala, Pekka A.
Selander, Tuomas A.
Kuitunen, Hanne K.
Kantanen, Anne-Mari
Kuittinen, Outi M.
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 627 - 634
[34] Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up
Pulczynski, Elisa Jacobsen
Simonsen, Mikkel Runason
Kuittinen, Outi
Fagerli, Unn-Merete
Erlanson, Martin
Fluge, Oystein
Leppa, Sirpa
Ostenstad, Bjorn
Fossa, Alexander
Eriksson, Mikael
El-Galaly, Tarec
Kuitunen, Hanne
Papworth, Karin
Ljungqvist, Maria
Pedersen, Martin B.
Pollari, Marjukka
REVISTA CHILENA DE LITERATURA, 2024, (109): : 2359 - 2363
[35] Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up
Pulczynski, Elisa Jacobsen
Simonsen, Mikkel Runason
Kuittinen, Outi
Fagerli, Unn-Merete
Erlanson, Martin
Fluge, Oystein
Leppa, Sirpa
Ostenstad, Bjorn
Fossa, Alexander
Eriksson, Mikael
El-Galaly, Tarec
Kuitunen, Hanne
Papworth, Karin
Ljungqvist, Maria
Pedersen, Martin B.
Pollari, Marjukka
HAEMATOLOGICA, 2024, 109 (07) : 2359 - 2363
[36] Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis
Rule, Simon
Dreyling, Martin
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad S.
Hernandez-Rivas, Jose Angel
Londhe, Anil
Clow, Fong
Deshpande, Sanjay
Parisi, Lori
Wang, Michael
BLOOD, 2017, 130
[37] Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
Maruyama, Dai
Terui, Yasuhito
Yamamoto, Kazuhito
Fukuhara, Noriko
Choi, Ilseung
Kuroda, Junya
Ando, Kiyoshi
Hattori, Akira
Tobinai, Kensei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (11) : 1265 - 1273
[38] Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Schuster, Stephen J.
Fowler, Nathan
Dickinson, Michael
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie L.
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, Phoebe Joy
Perez-Simon, Jose A.
Chen, Andy
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres Jose Maria
Teshima, Takanori
Patten, Piers
McGuirk, Joseph P.
Petzer, Andreas L.
Offner, Fritz
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Zia, Aiesha
Awasthi, Rakesh
Paule, Ines
Germano, Davide
Ramos, Roberto Javier
Hsu, Pei
Thieblemont, Catherine
Dreyling, Martin
BLOOD, 2023, 142
[39] FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up
H. Palmedo
H. Urbach
H. Bender
U. Schlegel
I. G. H. Schmidt-Wolf
A. Matthies
M. Linnebank
A. Joe
J. Bucerius
H.-J. Biersack
H. Pels
European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 164 - 168
[40] FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up
Palmedo, H
Urbach, H
Bender, H
Schlegel, U
Schmidt-Wolf, IGH
Matthies, A
Linnebank, M
Joe, A
Bucerius, J
Biersack, HJ
Pels, H
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (02) : 164 - 168

← 1 2 3 4 5 →